ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 28 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $38,000 | -5.0% | 10,000 | 0.0% | 0.00% | -66.7% |
| Q3 2019 | $40,000 | -4.8% | 10,000 | 0.0% | 0.00% | +50.0% |
| Q2 2019 | $42,000 | -39.1% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $69,000 | -34.9% | 10,000 | -65.2% | 0.00% | -66.7% |
| Q4 2018 | $106,000 | -41.8% | 28,700 | 0.0% | 0.01% | -40.0% |
| Q3 2018 | $182,000 | -1.1% | 28,700 | +17.9% | 0.01% | -9.1% |
| Q2 2018 | $184,000 | +124.4% | 24,343 | +138.7% | 0.01% | +120.0% |
| Q1 2018 | $82,000 | – | 10,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |